<DOC>
	<DOCNO>NCT00390299</DOCNO>
	<brief_summary>This phase I trial study side effect best dose carcinoembryonic antigen-expressing measles virus ( MV-CEA ) treat patient glioblastoma multiforme come back . A virus , call MV-CEA , change certain way , may able kill tumor cell without damage normal cell .</brief_summary>
	<brief_title>Viral Therapy Treating Patients With Recurrent Glioblastoma Multiforme</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To assess safety toxicity intratumoral resection cavity administration Edmonston 's strain measles virus genetically engineer produce CEA ( MV-CEA ) patient recurrent glioblastoma multiforme . II . To determine maximum tolerate dose ( MTD ) MV-CEA . III . To characterize viral gene expression dose level manifest CEA titer . IV . To assess viremia , viral replication , measles virus shedding/persistence follow intratumoral administration . V. To assess humoral cellular immune response inject virus . VI . To assess preliminary fashion antitumor efficacy approach . OUTLINE : This dose-escalation study . Patients assign 1 2 sequential treatment arm . ARM A ( RESECTION CAVITY ADMINISTRATION ) : Patients undergo en block resection tumor ( confirm diagnosis ) day 1 , follow MV-CEA administered resection cavity . ARM B ( INTRATUMORAL AND RESECTION CAVITY ADMINISTRATION ) : Patients undergo stereotactic biopsy ( confirm diagnosis ) placement catheter within tumor , follow carcinoembryonic antigen-expressing measles virus intratumorally ( IT ) catheter 10 minute day 1 . Patients undergo en block resection tumor computer-assisted stereotactic technique day 5 , follow MV-CEA administer around tumor bed . After completion study treatment , patient follow 28 day ( non-cohort I patient ) , 7 week ( patient cohort I ) , every 2 month progression , every 3 12 month progression , yearly thereafter 15 year .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Astrocytoma</mesh_term>
	<mesh_term>Oligodendroglioma</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<criteria>Recurrent grade 3 4 glioma , include astrocytoma , oligodendroglioma mixed glioma histologic confirmation initial diagnosis recurrence Candidate gross total subtotal resection Absolute neutrophil count ( ANC ) &gt; = 1500/uL Platelets ( PLT ) &gt; = 100,000/uL Total bilirubin = &lt; 1.5 x upper normal limit ( ULN ) Aspartate aminotransferase ( AST ) = &lt; 2 x ULN Creatinine = &lt; 2.0 x ULN Hemoglobin ( Hgb ) &gt; = 9.0 gm/dL Prothrombin time ( PT ) activate partial thromboplastin time ( aPTT ) = &lt; 1.3 x ULN Ability provide inform consent Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 0 , 1 2 Antimeasles virus immunity demonstrate immunoglobulin G ( IgG ) antimeasles antibody level &gt; = 1.1 EU/ml determine enzyme immunoassay Normal serum CEA level ( &lt; 3 ng/ml ) time registration Willing provide biologic specimen require protocol Negative serum pregnancy test do = &lt; 7 day prior registration ( woman childbearing potential ) Any follow : Pregnant woman Nursing woman Men woman childbearing potential unwilling employ adequate contraception Active infection = &lt; 5 day prior registration History tuberculosis history purify protein derivative ( PPD ) positivity Any follow therapy : Chemotherapy = &lt; 4 week prior registration ( 6 wks nitrosoureabased chemotherapy ) Immunotherapy = &lt; 4 week prior registration Biologic therapy = &lt; 4 week prior registration Bevacizumab = &lt; 12 week prior registration Noncytotoxic antitumor drug , i.e. , small molecule cell cycle inhibitor = &lt; 2 week prior registration Radiation therapy = &lt; 6 week prior registration Any viral gene therapy prior registration Failure fully recover acute , reversible effect prior chemotherapy regardless interval since last treatment New York Heart Association classification III IV Requiring blood product support Inadequate seizure control Expected communication ventricle resection cavity result surgery Human immunodeficiency virus ( HIV ) positive test result , history immunodeficiency History organ transplantation History chronic hepatitis B C Other concurrent chemotherapy , immunotherapy , radiotherapy ancillary therapy consider investigational ( utilized nonFood Drug Administration [ FDA ] approve indication context research investigation ) Exposure household contact = &lt; 15 month old household contact know immunodeficiency Allergy measles vaccine history severe reaction prior measles vaccination</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>